| Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm N Pemmaraju, AA Lane, KL Sweet, AS Stein, S Vasu, W Blum, DA Rizzieri, ... New England Journal of Medicine 380 (17), 1628-1637, 2019 | 349 | 2019 |
| Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients MT Cibeira, V Sanchorawala, DC Seldin, K Quillen, JL Berk, LM Dember, ... Blood, The Journal of the American Society of Hematology 118 (16), 4346-4352, 2011 | 348 | 2011 |
| Indications, complications, and management of inferior vena cava filters: the experience in 952 patients at an academic hospital with a level I trauma center S Sarosiek, M Crowther, JM Sloan JAMA internal medicine 173 (7), 513-517, 2013 | 262 | 2013 |
| Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience V Sanchorawala, F Sun, K Quillen, JM Sloan, JL Berk, DC Seldin Blood, The Journal of the American Society of Hematology 126 (20), 2345-2347, 2015 | 141 | 2015 |
| SARS-CoV-2 Infection–Associated Hemophagocytic Lymphohistiocytosis: An Autopsy Series With Clinical and Laboratory Correlation A Prilutskiy, M Kritselis, A Shevtsov, I Yambayev, C Vadlamudi, Q Zhao, ... American journal of clinical pathology 154 (4), 466-474, 2020 | 139 | 2020 |
| Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study V Sanchorawala, S Sarosiek, A Schulman, M Mistark, ME Migre, R Cruz, ... Blood, The Journal of the American Society of Hematology 135 (18), 1541-1547, 2020 | 133 | 2020 |
| Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial DJ Winston, KM Mullane, OA Cornely, MJ Boeckh, JW Brown, SA Pergam, ... The Lancet 391 (10135), 2116-2127, 2018 | 98 | 2018 |
| Hematopoietic cell transplantation for plasmablastic lymphoma: a review MM Al-Malki, JJ Castillo, JM Sloan, A Re Biology of Blood and Marrow Transplantation 20 (12), 1877-1884, 2014 | 95 | 2014 |
| Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial V Sanchorawala, AC Shelton, S Lo, C Varga, JM Sloan, DC Seldin Blood, The Journal of the American Society of Hematology 128 (8), 1059-1062, 2016 | 89 | 2016 |
| Induction therapy with bortezomib followed by bortezomib-high dose melphalan and stem cell transplantation for light chain amyloidosis: results of a prospective clinical trial V Sanchorawala, D Brauneis, AC Shelton, S Lo, F Sun, JM Sloan, ... Biology of Blood and Marrow Transplantation 21 (8), 1445-1451, 2015 | 71 | 2015 |
| Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue with amyloid deposition: a clinicopathologic case series RJH Ryan, JM Sloan, AB Collins, J Mansouri, NS Raje, LR Zukerberg, ... American Journal of Clinical Pathology 137 (1), 51-64, 2012 | 69 | 2012 |
| Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial V Sanchorawala, JM Patel, JM Sloan, AC Shelton, JB Zeldis, DC Seldin Haematologica 98 (5), 789, 2013 | 66 | 2013 |
| Long-term outcome of kidney transplantation in AL amyloidosis A Angel-Korman, L Stern, S Sarosiek, JM Sloan, G Doros, ... Kidney international 95 (2), 405-411, 2019 | 64 | 2019 |
| Association between hypercoagulable conditions and calciphylaxis in patients with renal disease: a case-control study AS Dobry, LN Ko, J St John, JM Sloan, S Nigwekar, D Kroshinsky JAMA dermatology 154 (2), 182-187, 2018 | 56 | 2018 |
| Association between inferior vena cava filter insertion in trauma patients and in-hospital and overall mortality S Sarosiek, D Rybin, J Weinberg, PA Burke, G Kasotakis, JM Sloan JAMA surgery 152 (1), 75-81, 2017 | 53 | 2017 |
| A forgotten cause of kidney injury in chronic myelomonocytic leukemia TV Patel, HG Rennke, JM Sloan, DJ DeAngelo, DM Charytan American journal of kidney diseases 54 (1), 159-164, 2009 | 53 | 2009 |
| Assessment of minimal residual disease using multiparametric flow cytometry in patients with AL amyloidosis A Staron, EJ Burks, JC Lee, S Sarosiek, JM Sloan, V Sanchorawala Blood advances 4 (5), 880-884, 2020 | 48 | 2020 |
| Safety and efficacy of high-dose melphalan and auto-SCT in patients with AL amyloidosis and cardiac involvement S Girnius, DC Seldin, HK Meier-Ewert, JM Sloan, K Quillen, FL Ruberg, ... Bone marrow transplantation 49 (3), 434-439, 2014 | 47 | 2014 |
| Bortezomib and high-dose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study V Sanchorawala, K Quillen, JM Sloan, NT Andrea, DC Seldin Haematologica 96 (12), 1890, 2011 | 43 | 2011 |
| High-dose melphalan and stem cell transplantation for patients with AL amyloidosis: trends in treatment-related mortality over the past 17 years at a single referral center SB Tsai, DC Seldin, K Quillen, JL Berk, FL Ruberg, H Meier-Ewert, ... Blood, The Journal of the American Society of Hematology 120 (22), 4445-4446, 2012 | 39 | 2012 |
